Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intrahepatic Cholangiocarcinoma in a Patient with Hepatitis C: A Cautionary Tale.

Rhode Island medical journal (2013)·2020
Same author

Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma.

American journal of hematology·2019
Same author

Systemic Amyloidosis Mimicking Lung Cancer.

American journal of respiratory and critical care medicine·2019
Same author

Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy.

British journal of haematology·2019
Same author

A new onset of thrombocytopenia and microangiopathic hemolytic anemia in the healthcare setting: A challenge for diagnosis.

American journal of hematology·2018
Same author

Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.

Clinical lymphoma, myeloma & leukemia·2018
Same journal

Multidisciplinary Characterization of Rare MPL Y591 and R592 Variants in Myeloid Disorders: From Clinical Correlation and Literature-Based Evidence to In Silico Predictors and Structural Bioinformatics.

Experimental hematology·2026
Same journal

Integrin alpha 4 inhibition prolongs the survival of NSG mice engrafted with CD19-negative post-CART19 relapsed B-ALL.

Experimental hematology·2026
Same journal

RNA Binding Protein PCBP1 Functions in the Endothelial-to-Hematopoietic Transition During Hematopoietic Stem Cell Formation.

Experimental hematology·2026
Same journal

Image-enabled cell sorting permits prospective isolation of primitive hematopoietic stem cell subsets with distinct functional potential.

Experimental hematology·2026
Same journal

Inhibition of MLLT1 Limits Growth of KMT2A::AFF1 Leukemias Without Killing Healthy Hematopoietic Stem Cells.

Experimental hematology·2026
Same journal

Adaptive Immune Remodeling in Sickle Cell Disease: Linking Hemolysis-Driven Inflammation to Immune Dysfunction.

Experimental hematology·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Acute myelogenous leukemia.

Joshua L Shipley1, James N Butera

  • 1Department of Hematology/Oncology, Brown University, Providence, RI 02903, USA.

Experimental Hematology
|May 26, 2009
PubMed
Summary
This summary is machine-generated.

Acute myeloid leukemia (AML) treatments are improving, with newer targeted therapies offering hope for better long-term survival in patients with this complex blood cancer.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 22, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) is a diverse cancer with outcomes influenced by age, genetics, and overall health.
  • Standard treatments yield lower long-term survival rates in older adults, who represent the majority of diagnoses.

Purpose of the Study:

  • To review current standard treatments for AML.
  • To discuss emerging novel therapies targeting molecular abnormalities in AML.

Main Methods:

  • Literature review of standard and novel AML therapies.
  • Summary of treatment outcomes based on patient demographics and molecular profiles.

Main Results:

  • Standard induction therapy achieves complete remission in 60-80% of younger patients but only 40-55% of older adults.
  • Long-term disease-free survival remains a challenge, with rates of 20-30% in younger patients and lower in older adults.
  • Advances in understanding AML's molecular biology have spurred the development of targeted therapies.

Conclusions:

  • Novel therapies targeting specific molecular alterations show promise for improving AML treatment efficacy.
  • A deeper understanding of AML's heterogeneity is crucial for developing personalized and effective treatment strategies.